Therapeutic effect of epigallocatechin gallate on hyperlipidemic fatty liver in rats

Bin GE,Mei-lin XIE,Zhen-lun GU,Pei-gang QIAN,Wen-xuan ZHOU,Ci-yi GUO
DOI: https://doi.org/10.3321/j.issn:1001-1978.2009.04.023
2009-01-01
Abstract:Aim: To investigate whether epigallocatechin gallate (EGCG) had therapeutic effect on hyperlipidemic fatty liver and its possible mechanism in rats. Methods: Rat model with hyperlipidemic fatty liver was successfully established by feeding fatty milk for 6 weeks. The experimental rats were then treated with EGCG 10-40 mg·kg -1 for 6 weeks. The therapeutic and antioxidation effects of EGCG on hyperlipidemic fatty liver were observed. Histopathological changes of rat liver were observed under light and electron microscopy. Results: After treatment with EGCG, the rat serum levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein-cholesterol (LDL-C), free fatty acids (FFA), alanine transaminase (ALT) and aspartate transaminase (AST) were significantly decreased as compared with the fatty liver model group. The hepatic weight and its coefficient, the hepatic tissue contents of TC, TG, and malondialdehyde (MDA) in EGCG-treated groups were also significantly decreased, while the serum high density lipoprotein-cholesterol (HDL-C) and hepatic tissue contents of superoxide dismutase (SOD) were obviously increased. Importantly, the histological evaluation of rat liver demonstrated that EGCG dramatically decreased lipid accumulation. Conclusion: EGCG possesses the therapeutic effect on fatty milk-induced rat fatty liver, and the mechanism may be associated with its antioxidation.
What problem does this paper attempt to address?